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Abstract Bronchiolitis obliteranswithorganizingpneumonia (BOOP) is aninfrequentlyencounteredclinicalcondition
thatcanmimicanumberofotherpathologiclungprocesses.Thepresentationofthis treatable conditionincancerpatients
has not been described in any large series.We conducted a retrospective study of patients with BOOP at Memorial
Sloan^Kettering Cancer Center,NewYork,NY,U.S.A. from January1992 to December1999.The type and treatmentof
primary cancer, clinical and radiographic features of initial BOOP presentation, and outcome following therapy were
recorded. Forty-three patients with an underlying diagnosis of cancer were found on lung biopsy to have BOOP as an
isolatedentity.BOOPwasencounteredinpatientswith avarietyofclinicalpresentations, andmany typesofmalignancies.
The symptompatternswere non-speci¢c, aswere the physiological abnormalities.The only clear relationship between
theunderlyingmalignancyandthediagnosisof BOOPatpresentationwasinthechestradiographic ¢ndings.Patientswith
solid organ tumors weremore likely to have nodular ormass like radiographic abnormalities (81%) than to have di¡use
in¢ltrates (19%).We observed the opposite pattern in patients with hematologic malignancies (22% vs.67%).The vast
majorityof patients recovered fromthis condition.In conclusion,Forcancer patients,BOOPrepresents a treatable cause
of lungdiseasewith proteanmanifestations.BOOPcanmimic pulmonarymalignancy andpulmonary infection.In cancer
patients, the evaluation of newpulmonary symptoms accompanied byradiographic changes should include a considera-
tion of this diagnosis.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1269, available online at http://www.idealibrary.comon
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Patients with active or previously treated cancer who
develop new pulmonary symptoms or abnormal chest
radiographs are frequently encountered. Typically, the
¢rst concern is either progression of cancer or an infec-
tious process. In the past several years, bronchiolitis ob-
literans with organizing pneumonia (BOOP) has been
found to be the underlying lung process in some of these
patients. Lange, a German pathologist, ¢rst described
the pathological ¢ndings of BOOP in two autopsies in
1901(1). In1985,Epleretal. published the ¢rst comprehen-
sive clinical case series of these patients, identifying
BOOP as a distinct clinical entity with features of both
pneumonia and airways abnormalities (2).BOOP is char-
acterizedby the formation of granulation tissueplugs (i.e.
Masson bodies) within the lumen of small airways, alveo-Received 3 July 2001and accepted in revised form19 November 2001
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bachp@mskcc.orglar ducts and alveoli. These consist of rounded balls of
myxomatous connective tissue that form intra-luminal
polyps within bronchioles and air spaces. In£ammatory
cells including neutrophils, lymphocytes and plasma cells
are sometimes seen at the center of the intra-luminal
myxoid polyps. Other features include intra-alveolar
foamy macrophages, ¢brinous exudates and an intersti-
tial mononuclear cell in¢ltrate of variable density (3)
(Fig.1).
The underlying cause of BOOP remains unknown,
although its association with variety of conditions such
as bacterial (4), viral (5), parasitic (6) and fungal (7) infec-
tions, collagen vascular disease (8^11), drug toxicity (12)
and inhalation of toxic fumes (13) have all been described.
When BOOP has been reported in cancer patients, it
hasmostlybeen in the settingof allogeneic bonemarrow
transplanatation (14) or in breast cancer patients
receiving radiation therapy (15). A systematic association
with other types of cancer has not been reported. In
this study, we report the clinical manifestations, treat-
ment, and outcomes of a consecutive series of cancer pa-
tients with pathologically proven BOOP seen at our
institution.
FIG. 1. Pathology photomicrograph (H&E stain  20) of an open lung biopsy from a patient with leukemia and BOOP, showing a
¢broblastic plug ¢lling the air spaces andincludes foamymacrophages andin£ammatorycellswithinterstitialpneumonia and air space
¢brosis.
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Patient data
Patients with an antecedent or concomitant diagnosis of
cancer and pathological evidence of BOOP are the sub-
jects of this study.We report the clinical features, radio-
graphical abnormalities, treatment and outcome of
these patients, who received their care at Memorial
Sloan^Kettering Cancer Center (MSKCC) during the
years 1992^1999. These patients had undergone lung
biopsy for the evaluation of undiagnosed pulmonary no-
dules, masses or in¢ltrates. Although BOOP has fre-
quently been observed in the immediate vicinity of
other lung processes, the patients included in this series
all had the pathologic diagnosis of BOOP in an isolated
region of the lung, exclusive of malignancy, granuloma
or infection.Thepatientswere identi¢ed through a com-
puterized search of theMSKCCpathologydatabase, sup-
plemented by a search of pathological slides submitted
from other institutions. Those patients who did not re-
ceive their care at the MSKCC were excluded from the
study.
Patient information was abstracted from the paper
charts and computerized medical record system of
MSKCC. Age, sex, ethnicity, smoking history, cancer in-
formation such as date and method of the diagnosis,
stage, chemotherapeutic regimen, radiation treatment,
bonemarrow transplantation, conditioningregimens, in-
fection and graft versus host disease (GVHD) prophylac-
tic protocols, and complications of therapy were
documented.Symptoms and signs present at the time of diagnosis of
BOOP were abstracted from themedical record.Other
information, such as pulmonary function tests, radiogra-
phical ¢ndings and descriptions of histopathology were
adapted from the o⁄cial report. Treatments received
and patient outcomes, including radiographical changes
and survival time after BOOP diagnosis were obtained
from themedical charts and fromconversationswith pa-
tients and providers. Cause of death was determined
through the treating physician’s reports.
De¢nitions of variables
Pulmonary function
Pulmonary function tests included spirometry (before
and after bronchodilators, if indicated), lung volumes
and single-breath carbon monoxide di¡usion capacity
(DLCO). Spirometry was performed on aWarren E. Col-
lins modular unit using the standard spirometric techni-
ques. Volumes were determined by the closed-circuit
helium dilusion method. The DLCO was determined by
themethod ofOgilvie etal. and Cotes etal.Exercise test-
ing was done measuring pulse oximetry before, during
and after 30 sec of activity using the Masters two-step
staircase. Pulmonary function tests were performed
and interpretedbased on theAmericanThoracic Society
(ATS) criteria delineated in the ATS o⁄cial statement on
standardization of spirometry (16,17). Patients character-
ized as having oxygen desaturation were those who
dropped their oxygen saturation four or more
TABLE 1. Characteristics of 43 patients with pathologi-
cally proven bronchiolitis obliterans organizing pneumo-
nia (BOOP) between 1992 and 1999 at the Memorial
Sloan^Kettering Cancer Center
Age inyears (mean, range) 57 4 (20^89)
Sex
Male 29 (67%)
Female 14 (33%)
Race
Caucasian 36 (84%)
Hispanic 3 (7%)
Others 4 (9%)
Smokinghistory
Non-smokers 14 (32%)
20 pack-years ormore 21 (49%)
20 pack-years or less 8 (19%)
Malignancy
Solid organtumors 27 (63%)
Non-small cell lungcancer (NSCLCA) 8 (19%)
Small cell lungcancer 2 (5%)
Sarcoma 4 (10%)
Germcell 3 (7%)
Gastrointestinal 3 (7%)
Melanoma 2 (5%)
Prostate 1 (2%)
Thymoma 1 (2%)
Breast 1 (2%)
Multiplemalignancies
colon adenocarcinoma/transitional cell 1 (2%)
carcinoma ofthe urinarybladder
NSCLCA/prostate 1 (2%)
Hematologicmalignancies16 (37%)
Lymphoma 7 (16%)
Leukemia 9 (21%)
Allogeneic bonemarrow transplanation 9 (21%)
Leukemia 8 (19%)
Lymphoma 1 (2%)
282 RESPIRATORYMEDICINEpercentagepoints fromresting oxygen saturation during
1 5min on a Masters two-step staircase (18).
Radiographical features
The radiographical features were classi¢ed based on the
dimensions, distribution, and characteristics of the ab-
normality. A nodule was de¢ned as a well-circumscribed
lesion with the largest dimension measuring 3 cm or less
on plain chest radiography or CT scan. A mass was de-
¢ned as a well-circumscribed lesion greater than 3 cm in
its greatest dimension. In¢ltrative patterns were de¢ned
as vaguely circumscribed abnormalities of interstitial or
alveolar origin or consolidation with air-bronchogram
that involved one or more lobes.Ground glass attenua-
tion based on the CT ¢ndings, when available, were in-
corporated.
Pulmonary toxic agents
A history of radiation to the chest wall and a history of
receiving chemotherapeutics with known pulmonary
toxicity were identi¢ed from the patients’ charts and
correspondencewith other treating facilities. Agents ad-
ministered which were considered to have pulmonary
toxicity included: bleomycin, gemcitabine, mitomycin-C,
methotrexate, taxol, ATRA, ara-C, vinca alkaloids, ni-
trosoureas and alkylating agents, particularly cyclopho-
sphamide.
Outcome
Data regarding patient outcome such as symptomatic
andradiographic changes in response to therapy,mortal-
ity data related to respiratory decompensationwithin 30
days of BOOP diagnosis and other causes of deaths
unrelated to BOOP were documented from the
physician reports.
Statistical analysis
Most of the results presented in this paper are descrip-
tive in nature and are presented as summary statistics.
The exceptions include: association between underlying
malignancy and chest radiographical ¢ndings was evalu-
atedusing Fisher’s exact test (19) and changes in pulmon-
ary function tests over time were assessed using the
Student’s t-test (20). All P-values quoted are two-sided.
RESULTS
Study patients
Lung tissue specimens from 8519 were accessioned by
the Pathology Department of MSKCC between Febru-
ary 1992 and August 1999. Sixty-eight had pathologicalevidence of BOOP.Twenty-¢ve of the patients were ex-
cluded from the study because BOOP was located in a
region of another pathological process or processes.
Of the remaining 43 patients with isolated BOOP,
pathological specimens were obtained by surgical
resection or open lung biopsy through formal thoracot-
omy in 29 (68%) patients, video-assisted thoracoscopic
surgery (VATS) in 10 (23%) patients and transbronchial
biopsy through ¢ber-optic bronchoscopy in four (9%) pa-
tients.
Themean age of the patientswas 57 4 (20^89) years.
White males with history of 20 or more pack-years of
smoking formed the major group. The study patients
had a wide variety of malignancies. Twenty-seven (63%)
had solid organ tumors and 16 (37%) had hematological
malignancies with some form of leukemia or lymphoma;
nine (21%) and seven (16%) respectively (Table1).
TABLE 2. Common pulmonary and non-pulmonary
symnptom(s) reported by the 43 patientswith bronchio-
litis obliterans organizingpneumonia andmalignancy
Symptoms
Cough 26 (60%)
Sputum 17 (39%)
Dyspnea 16 (37%)
Fever 13 (30%)
Chest pain 3 (7%)
Cough, dyspnea, sputumand fever 14 (33%)
Hemoptysis 2 (5%)
Generalized fatigue 4 (9%)
None 10 (23%)
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All patients had undergone treatment for their malig-
nancy. Thirty-one (72%) patients received more than
one mode of treatment. Eight had chemotherapy and
surgery, six had chemotherapy and radiation, three had
radiation followedby surgery, ¢ve had chemotherapy, ra-
diation and surgery and nine underwent allogeneic bone
marrow transplantation after preparation with che-
motherapy and total body irradiation.Of those patients
who received single modality treatment, seven had sur-
gery and ¢ve had chemotherapy.
Nine of the patients in our series had a history of re-
ceiving radiation therapy. Two had extra-thoracic radia-
tion only and these individuals developed BOOP 2^3
years after their treatment.Of the sevenwho had radia-
tion therapy to the chest, all developedBOOPwithin120
days (BOOPwas found ipsilateral to theradiationport in
¢ve of these patients).
Thirty-one (74%) patients had chemotherapy. Vincris-
tine, cisplatin, cyclophosphamide and taxol were the
most frequent agents used as a single or combination
therapy in descending order. In total15 (35%) patients re-
ceived agents with known pulmonary toxicity and only
three patients received bleomycin, an agent that has
been reported to have an association with BOOP (21).
Other chemotherapeutic agents such as ifosfamide, vel-
ban, methotrexate and mitomycin were used with less
frequency in this population.
Clinical presentation of BOOP
Clinical symptoms (Tables 2 and 3)
Symptomswere experienced by 33 (77%) of patients, in-
cluding cough (60%), sputum production (39%) and dys-
pnea (38%). In only half of these patients (17 of 33) was
fever a prominent component. Chest pain (7%) and
hemoptysis (5%) were relatively rare. Generalized fati-TABLE 3. Relationship of the radiographical ¢ndings to sympto
malignancy
Symptoms,Treatment and Outcome n (% to
Symptoms
Symptomatic 33/43 (
Asymptomatic 10/43 (
BOOP treatment
Nomedical treatment 21/43
Steroids 20/43
Macrolides 2/43
Outcome
Treated and alive by the end of study 29/43
BOOPunrelated death 11/43
Respiratorydeath (within 30 days of BOOP diagnosis) 3/43gue was the predominant non-pulmonary symptom.
Symptoms were more common in patients with in¢ltra-
tive radiographic ¢nding (14 of 15) compared with those
who had nodules ormasses (19 of 28).
Chest radiographical ¢ndings
The study subjects had a variety of chest radiographical
abnormalities.We noted an association between the un-
derlyingmalignancy and radiographic ¢nding that did not
reach statistical signi¢cance (P=0 15). The majority of
patients with solid organ tumors had nodules or masses
as the manifestation of BOOP. In contrast, BOOP in pa-
tients with hematological malignancies were more likely
to appear as an in¢ltrative pattern on chest radiographs
(Figs 2 and 3).
Pulmonary function data
Twenty-¢ve (58%) patients had pulmonary function test-
ing (PET) prior to the diagnosis of BOOP.Thirteen (30%)
patients demonstrated obstructive ormixed ventilatoryms, treatment and outcome in 43 patients with BOOP and
tal) Chest radiographical features
Nodular/mass-like, n=28 (65%) In¢ltrate, n=15 (35%)
77%) 19/28 (68%) 14/15 (93%)
23%) 9/28 (32%) 1/15 (7%)
(49%) 19/28 (68%) 2/15 (13%)
(46%) 8/28 (28%) 12/15 (80%)
(5%) 1/28 (4%) 1/15 (7%)
(67%) 24/28 (86%) 5/15 (33%)
(26%) 4/28 (14%) 7/15 (47%)
(7%) 0/28 (0%) 3/15 (20%)
FIG. 3. Abargraphillustrating therelationship ofradiographi-
calpatterns and the type of underlyingmalignancyin 43 patients
with cancer and BOOP. Nodules (&), mass ( ) and in¢ltrate
(&).
FIG. 2. CTscans of the chest in three patientswithmalignancy
and BOOPon open lung biopsy or resection. (a) A patient with
testicular cancer and pulmonary nodules, (b) mass in the right
upper lung ¢eld in a patient after lobectomy for NSCLCA and
(c) nodular in¢ltrate in a patient with acutemyelogenous leuke-
mia duringchemotherapy.
284 RESPIRATORYMEDICINEdefects; of these, nine (70%) had greater than 20 pack-
years of smoking. In contrast, only two patients had iso-
latedrestrictive defects; the PFTabnormalitymost com-
monly associated with BOOP (2). For the 17 (39%)
patientswith available post-treatment PFT, we observed
small but consistent declines in forced vital capacity
(FVC), forced expiratory volume in 1sec (FEV1) andDLCO that were not statistically signi¢cant (data not
shown). Exercise oxygen desaturation was noted in ¢ve
(12%) patients.One patient in this group had hematologi-
calmalignancy with di¡use in¢ltrative chestradiographic
¢ndings. The rest were in the solid organ tumor group
with smoking history and nodular chest radiographic ab-
normalities.
Antecedent infections
A total of four patients had antecedent evidence of pul-
monary cytomegalovirus (CMV) disease detected from
bronchoscopy specimens. All of these patients had re-
ceived allogenic bone marrow transplantation before
1994.We have not seen any pulmonary CMV disease in
this series after1994.Other infections encounteredin as-
sociation with BOOP at diagnosis were Cryptococcosis
neoformans, Pneumocystis carinii, Hemophillus in£uenza
and Mycofacterium, tuberculosis, each found in one pa-
tient.
Patient treatment and outcome
Twenty-one (49%) patients received no speci¢c medical
therapy.Of these, sixteen (76%) patients had solid organ
tumor and ¢ve (24%) had hematological malignancies. In
this group10 (23%) patients were asymptomatic and the
remainder had resolution of their symptoms after surgi-
cal resection of lung lesion(s). Of the symptomatic pa-
tients, 20 (46%) patients were treated with
corticosteroids for a minimumperiod of 4 months (typi-
cal dose 40^60mg of prednisone per day) and two (5%)
receivedmacrolides due to steroid intolerance. Seventy-
¢ve per cent ofmedically treatedpatients had hematolo-
gical malignancy whereas amongst patients with solid
organ tumor 29% required medical therapy for their
BOOP INCANCERPATIENTS 285BOOP. Three (7%) patients died of a respiratory cause
within1month of BOOP diagnosisFall of these patients
belong to the hematologicalmalignancygroup, hadmore
severe respiratory symptoms, had in¢ltrative pattern on
chest radiographs and required steroid therapy. Eleven
(26%) patients died due to causes unrelated to BOOP
while 29 (67%) became symptom-free and had complete
normalization of their chest radiographs. Of these pa-
tients,14 (47%) had never received treatment for BOOP,
while the remainder had received either corticosteroids
or macrolide therapy. One patient demonstrated radio-
graphical relapse of BOOP thatwas attributed to steroid
intolerance. This patient had subsequently complete
symptomatic and radiographical resolution of her dis-
ease after low dose macrolide therapy. Pathologically
proven relapse has not been documented in this group
to date.
DISCUSSION
Patients with pulmonary abnormalities who have either
antecedent or ongoing cancer are frequently encoun-
tered in our medical center. This study focuses on the
clinical presentation and outcome of those patients with
radiographical abnormalities who ultimately were found
to have pathologically proven BOOP. We identi¢ed 43
cases of isolated BOOP from a total of 8519 lung patho-
logical slides that were accessioned between 1992 and
1999 at the Memorial Sloan^Kettering Cancer Center.
Cordier et al. divided patients with BOOP in to two
groupsbasedonradiographic patterns andused this clas-
si¢cation topredictoutcome in eachgroup.Patientswith
localized diseasewere rarely symptomatic and had over-
all a good prognosis, whereas patients with di¡use dis-
ease were more often symptomatic, required
treatment with corticosteroids and had variable out-
comes (12).Through this study we have also observed a
similar radiographical distinction. Furthermore, we
found that the type of the underlying malignancy fre-
quently could be correlated to the clinical course, radio-
graphical ¢ndings andpatientoutcome.We classi¢ed our
patients with malignancy and BOOP into two major ca-
tegories, those with solid organ tumors and those with
hematological malignancies. The majority of patients
with solid organ tumors had nodular or mass-like radio-
graphical ¢ndings, were either asymptomatic or had
minimal respiratory symptoms, did not require treat-
ment, andhadbetter outcomes.Thepatientswith hema-
tological malignancies more frequently had patchy or
di¡use in¢ltrative chest radiographical ¢ndings, had pro-
nounced respiratory symptoms (particularly those with
leukemia who underwent allogenic bone marrow trans-
plantation), required antiin£ammatory therapy for
BOOP and had complicated course. All three BOOP-re-
latedmortalities occurred in this group.The close correlation of the clinical course and out-
comewith the underlyingmalignancymay be due to sev-
eral factors. In patients with hematologicalmalignancies,
the pulmonary disease is usually more advanced at pre-
sentation as evidenced by the di¡use rather than loca-
lized in¢ltrates. Because of the di¡use nature of BOOP
in this group, and often the low pulmonary reserve sec-
ondary to extensive prior chemotherapy and/or chest ir-
radiation, surgical resection is not an option.
There have been many reports of BOOP in associa-
tion with infectious diseases. Several patients in our
study had previous cytomegalovirus infection and one
had Hemophillus in£uenza infection.We were, however,
unable to identify a statistically signi¢cant relationship
between any speci¢c pathogen and the development of
BOOP. Furthermore, we were unable to determine any
statistically signi¢cant correlation between the occur-
rence of BOOP in malignancy and any particular che-
motherapeutic agent or thoracic irradiation. In a large
number of patients pulmonary function testing indicated
a pattern of obstructive airways disease that was likely
due to the smoking. Presence of in¢ltrates or consolida-
tion on the chest roentgenograms did not correlatewith
a restrictive ventilatory defect on pulmonary function
studies.
Approximately half of our patients were given speci¢c
treatment for BOOP and the vast majority of these re-
ceived corticosteroid therapy.Two patients were mana-
ged successfully with low dose macrolides alone
secondary to steroid intolerance.The idiopathic form of
BOOP has excellent prognosis with a mortality of less
than 5% (22).The higher BOOP relatedmortality in our
group (7%), is probably multifactorial. Prior lung injury
secondary to chemotherapy, chest irradiation and over-
all altered immune status due to the malignant process
or long term steroid therapy, particularly in patients
with hematological malignancies, in part may have
caused a poorer outcome. Because macrolides could be
potentially o¡ered as a steroid-sparing agent, secondary
to their inherent anti-in£ammatory property, studies
should be undertaken to evaluate their e⁄cacy in treat-
ment of BOOP.
There are some limitations to this study.The true inci-
dence of BOOP in cancer patients cannot be deter-
mined. We only reviewed the patients who were
diagnosed from a lung biopsy. Presumably, we have pro-
vided care to a number of patients with BOOP based on
clinical and radiographical suspicionwithout a pathologi-
cal diagnosis. In addition, the outcome datawepresent is
limited in some cases by the level of detail we were able
to obtain from telephone interviews of patients and out-
side providers in some cases.
When confronted with a cancer patient with a new
pulmonaryprocess, the typical concerns are either infec-
tion or progression ofmalignancy. In our patients, BOOP
presented in a variety of ways that might be consistent
286 RESPIRATORYMEDICINEwith one of these two diagnoses. As the treatment of
BOOP is di¡erent from these other conditions, and the
anticipatedoutcomegivenproper treatment is excellent,
clinicians should consider this diagnosis when evaluating
a cancer patient with a new pulmonary process.The as-
sociationwe have notedbetween radiographical appear-
ance and underlyingmalignancy should also be helpful in
this clinical situation.
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